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Repressor element 1 (RE1)-silencing transcription factor (REST)/neuron-restrictive silencer factor (NRSF) can
repress several terminal neuronal differentiation genes by binding to a specific DNA sequence (RE1/
neuron-restrictive silencer element [NRSE]) present in their regulatory regions. REST-VP16 binds to the same
RE1/NRSE, but activates these REST/NRSF target genes. However, it is unclear whether REST-VP16
expression is sufficient to cause formation of functional neurons either from neural stem cells or from
heterologous stem cells. Here we show that the expression of REST-VP16 in myoblasts grown under muscle
differentiation conditions blocked entry into the muscle differentiation pathway, countered endogenous
REST/NRSF-dependent repression, activated the REST/NRSF target genes, and, surprisingly, activated other
neuronal differentiation genes and converted the myoblasts to a physiologically active neuronal phenotype.
Furthermore, in vitro differentiated neurons produced by REST-VP16-expressing myoblasts, when injected into
mouse brain, survived, incorporated into the normal brain, and did not form tumors. This is the first instance
in which myoblasts were converted to a neuronal phenotype. Our results suggest that direct activation of
REST/NRSF target genes with a single transgene, REST-VP16, is sufficient to activate other terminal neuronal
differentiation genes and to override the muscle differentiation pathways, and they suggest that this approach
provides an efficient way of triggering neuronal differentiation in myoblasts and possibly other stem cells.
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Neuroregeneration is being studied intensely as a way to
repair and restore damaged or diseased neurons. One ap-
proach is to manipulate various factors that control the
ability of neural stem cells (NSCs) in the adult brain to
regenerate neurons (Keyoung et al. 2001; Horner and
Gage 2002; Ourednik et al. 2002; Panchision and McKay
2002; Park et al. 2002a,b; Galli et al. 2003; Goldman
2003; Nunes et al. 2003). Another approach is to convert
nonneural stem cells or progenitor cells to the neuronal
phenotype through transdifferentiation. Embryonic stem
cells (ESCs) and bone marrow stem cells have been used
for this purpose (Snyder and Vescovi 2000; Frisen 2002;
Sanchez-Ramos 2002; Tsai et al. 2002; Brivanlou et al.
2003). Conversion of heterologous stem cells other than
ESCs to neurons would have a tremendous impact, given
the political and ethical concerns attending therapeutic
use of human ESCs (Wurmser and Gage 2002). However,
in some cases, formation of neurons from bone marrow
stem cells may be due to fusion of contaminating ESCs
rather than actual transdifferentiation (Wurmser and
Gage 2002), highlighting the importance of using a ho-
mogenous stem cell population for transdifferentiation
experiments.
C2C12 myoblasts are an excellent, well characterized
mouse model for muscle differentiation (Walsh and
Perlman 1997). When cultured with high concentrations
of growth factors, these homogeneous cells proliferate as
mononucleated progenitor cells. In contrast, when cul-
tured with low concentrations of growth factors, they
enter the differentiation pathway, express muscle differ-
entiation proteins, and fuse to form terminally differen-
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tiated, multinucleated myotubes. The molecular mecha-
nisms responsible for this differentiation process have
been studied extensively. Although less examined, under
certain conditions C2C12 myoblasts can also differenti-
ate into adipocyte-like cells (Teboul et al. 1995) or into
an osteoblast lineage (Katagiri et al. 1994). The spectacu-
lar dedifferentiation of terminally differentiated C2C12
myotubes into proliferating mononucleated cells and
their subsequent redifferentiation into cells expressing
myogenic, chondrogenic, adipogenic, and osteogenic
markers (Odelberg et al. 2000; McGann et al. 2001) make
C2C12 myoblasts an excellent yet simple system for
studying principles of stem cell plasticity. Although
these cells can differentiate and dedifferentiate into vari-
ous cell types, C2C12 myoblasts or dedifferentiated
myotubes do not give rise to neuronal cells, suggesting
that certain necessary factors are absent, negative factors
are present, or both.
The differentiation of NSCs into neurons is generally
believed to involve four steps characterized by the ex-
pression and action of specific gene products (Immaneni
et al. 2000; Lawinger et al. 2000). In the first step, NSCs,
which can multiply and make their own kind under one
set of conditions and differentiate under other condi-
tions, express p75 and nestin. The next step, the neuro-
nal determination step, is characterized by the action of
the basic helix-loop-helix proteins, such as MASH,
MATH, and neuroD3/neurogenin. This is followed by
the commitment step, in which gene products such as
neuroD1/2, Myt1, and neurofilament 150 are expressed.
The terminal differentiation step is characterized by the
expression of gene products such as SCG10, sodium
channel type II, synapsin, glutamate receptor, and ace-
tylcholine receptor. It is mostly the terminal differentia-
tion genes that are direct targets of the repressor element
1 (RE1)-silencing transcription factor (REST)/neuron-re-
strictive silencer factor (NRSF; Chong et al. 1995;
Schoenherr and Anderson 1995). REST/NRSF contains a
DNA-binding domain and two repressor domains and is
expressed mostly in nonneuronal cells. It blocks tran-
scription of its target genes by binding to a specific con-
sensus RE1-binding site/neuron-restrictive silencer ele-
ment (RE1/NRSE) present in the genes’ regulatory re-
gions. REST/NRSF is down-regulated during the
induction and maintenance of the neuronal phenotype
(Ballas et al. 2001), and overexpression of REST/NRSF in
differentiating neurons disrupts neuronal gene expres-
sion and causes axon guidance errors (Paquette et al.
2000).
Neuronal differentiation is regulated, particularly at
the beginning stages, by some negative regulators (Ross
et al. 2003). This raises the possibility that if we can
bypass these steps and directly activate terminal differ-
entiation genes, NSCs that are otherwise restricted at
the preceding steps can then differentiate into neurons.
Furthermore, such a manipulation could also convert
nonneural progenitor cells to a neuronal phenotype. To
examine this possibility, we previously constructed a re-
combinant transcription factor, REST-VP16, by replac-
ing the repressor domains of REST/NRSF with the acti-
vation domain of the herpes simplex virus protein VP16.
Because REST-VP16 still contains the DNA-binding do-
main of REST/NRSF, we found that REST-VP16, when
transiently expressed in mammalian cells, operates
through the RE1/NRSE, competes with endogenous
REST/NRSF for DNA binding, and activates REST/
NRSF target genes (Immaneni et al. 2000; Lawinger et al.
2000).
Although NSCs have been converted into muscles
(Galli et al. 2000, 2003), muscle progenitor cells have
shown tremendous potential in the treatment of muscle
and connective-tissue disorders (Deasy et al. 2001; Peng
and Huard 2003), and muscle-derived stem cells have
been converted into hematopoietic cells (Jankowski et
al. 2002; Cao et al. 2003), muscle progenitor cells have
not been converted into neurons. Here, we asked
whether direct activation of REST/NRSF target genes via
REST-VP16 can convert C2C12 myoblasts to the neuro-
nal phenotype.
Results
REST-VP16 counters endogenous REST/NRSF activity
in myoblasts
To determine whether C2C12 cells express endogenous
REST/NRSF activity and, if present, to quantify this ac-
tivity, we used two reporter plasmid DNAs that we used
previously (Immaneni et al. 2000; Lawinger et al. 2000).
The first is pNaCh (also called pSDK7), which contains
the bacterial chloramphenicol acetyl transferase (CAT)
reporter gene under the control of sodium channel type II
promoter/enhancer (NaCh) elements (Chong et al. 1995).
The NaCh elements are mammalian native neuronal
promoter/enhancer sequences that contain the REST/
NRSF-binding site (+RE) and are acted on by functional
REST/NRSF (Chong et al. 1995). The second reporter
plasmid, pNaChRE1 (also called pMB4), contains the
CAT reporter gene under the control of the “minimal”
NaCh elements without the RE1 sequence (−RE). Func-
tional REST/NRSF does not repress the promoter activ-
ity from this plasmid (Chong et al. 1995). Thus, when
functional REST/NRSF is present in the cell, the CAT
activity from pNaCh (+RE) would be lower than that
from pNaCh (−RE). In this experiment, we also used
PC12 cells, which do not express endogenous REST/
NRSF, and HeLa cells, which express endogenous REST/
NRSF (Chong et al. 1995; Schoenherr and Anderson
1995; Immaneni et al. 2000; Lawinger et al. 2000). These
cells were transiently cotransfected with the reporter
plasmids pNaCh (+RE) or pNaCh (−RE) and an internal
control plasmid, pCMV-gal, which contains the -gal-
actosidase reporter gene under the control of cytomega-
lovirus promoter. The average CAT values, normalized
to -galactosidase activity, from three experiments were
denoted as a percentage of pNaCh (−RE) promoter activ-
ity. As shown in Figure 1A, whereas PC12 cells did not
show REST/NRSF activity, HeLa cells did, as expected.
Under these conditions, C2C12 cells showed high endog-
enous REST/NRSF activity.
To determine whether transient expression of REST-
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VP16 in C2C12 cells could counter endogenous REST/
NRSF-dependent repression and cause stimulation of the
RE-dependent promoter activity, we carried out the tran-
scriptional assays using pNaCh (+RE) and pNaCh (−RE)
in these cells as described above. Vector DNA and plas-
mid DNA encoding REST or Gal4-VP16 were used as
control DNA. As shown in Figure 1B, none of the plas-
mids affected the NaCh (−RE) promoter activity. In con-
trast, the NaCh (+RE) promoter activity, compared with
NaCh (−RE), was repressed in the presence of the vector,
pREST, and pGal4-VP16 plasmids, indicating endog-
enous REST/NRSF activity. On the other hand, pREST-
VP16 could stimulate NaCh (+RE) promoter activity, in-
dicating that REST-VP16 can functionally counter the
endogenous REST/NRSF-dependent repression and
stimulate the RE-dependent promoters in C2C12 cells,
as was seen in other cell types (Immaneni et al. 2000;
Lawinger et al. 2000).
Stable REST-VP16 expression in proliferating
myoblasts causes activation of neuronal
differentiation genes
To investigate the role of long-term expression of REST-
VP16 in myoblasts, we generated C2C12 clonal cells by
using the bidirectional doxycycline-regulated vector
pBig2r (Strathdee et al. 1999). The clonal cell line
C2C12-RV stably expressed the REST-VP16 protein
when grown without doxycycline (−Dox) for 2 d, as
shown by Western blotting (Fig. 2A). In contrast, C2C12
(−Dox) cells and C2C12-RV cells grown with doxycy-
cline (+Dox) did not produce detectable levels of REST-
VP16 protein.
To determine whether the REST-VP16 protein was
transcriptionally active in the clonal cells, we used a
reporter plasmid system that we devised previously (Im-
maneni et al. 2000; Lawinger et al. 2000). We transfected
plasmids containing a luciferase reporter gene under the
control of a TATA box alone (pT.luc) or a TATA box plus
two copies of the wild-type RE1/NRSE sequence
(pRE.T.luc) into C2C12 and C2C12-RV (+ and −Dox)
cells. These experiments showed that C2C12-RV (−Dox)
cells activated the REST-dependent basal promoter 145-
fold more strongly than C2C12 cells (+ or −Dox) did and
20-fold more strongly than C2C12-RV (+Dox) cells (Fig.
2B). Thus, C2C12-RV (−Dox) cells produced high levels
of transcriptionally functional REST-VP16 protein.
To determine whether the REST-VP16 protein pro-
duced in the clonal cells activated its cellular target, the
terminal neuronal differentiation genes, we assayed the
Western blot in Figure 2A with an anti-synapsin anti-
body. As shown in Figure 2A, strong synapsin expression
Figure 1. Myoblasts express REST/NRSF activity, which can
be countered by REST-VP16. (A) C2C12 cells express endog-
enous REST/NRSF activity. Endogenous REST/NRSF activity
was determined in C2C12 cells, PC12 cells (negative control),
and HeLa cells (positive control) by transfection of a reporter
plasmid containing the CAT reporter gene under the control of
endogenous NaCh promoter with (+RE) or without (−RE) the
REST/NRSF-binding site. In these experiments, cotransfection
of an internal control plasmid, pCMV--gal, was used. The av-
erage CAT values, normalized to -galactosidase activity, from
triplicate experiments are shown as a percent of NaCh (−RE)
promoter activity. (B) The endogenous REST/NRSF activity in
C2C12 cells can be countered by REST-VP16. Expression vector
(Vector) and expression vector encoding REST/NRSF (pREST),
Gal4-VP16 (pGal4-VP16), and REST-VP16 (pREST-VP16) were
cotransfected with NaCh (+RE) or NaCh (−RE) reporter plas-
mids in C2C12 cells and the promoter activity was determined
as in A. The value for NaCh (−RE) in the presence of vector
DNA was denoted as 100%.
Figure 2. Stable REST-VP16 expression in proliferating myo-
blasts causes activation of neuronal differentiation genes. (A)
C2C12-REST-VP16 clonal cells (C2C12-RV) produced the
REST-VP16 protein in the absence of doxycycline (−Dox) as as-
sayed by Western blotting using anti-VP16 antibodies. Such
REST-VP16 production was not observed in the parental C2C12
cells or C2C12-RV cells in the presence of doxycycline (+Dox).
When the same blot was probed with anti-synapsin antibody,
expression of synapsin was observed in C2C12-RV(−Dox) cells
but not in C2C12 cells. A low level of synapsin signal was also
observed in C2C12-RV (+Dox) clones, presumably as a result of
the leakiness of the doxycycline-regulated system. Expression
of actin was measured as an internal control by using anti-actin
antibodies. (B) The C2C12-RV (−Dox) cells producing the REST-
VP16 protein can activate the basal TATA-box promoter
through the RE1-binding sites. The cells were transfected with
the reporter plasmid pTluc or pRE.Tluc along with an internal
control plasmid, PCMV--gal, and analyzed as described in the
Materials and Methods section. REST-VP16-dependent stimu-
lation was calculated as pRE.Tluc expression/pTluc expression,
and is shown as relative luciferase activity.
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was detected only in REST-VP16-expressing cells, indi-
cating that REST-VP16 activated its cellular target genes
in C2C12-RV (−Dox) cells. Interestingly, a low level of
synapsin expression was also detected in C2C12-RV
(+Dox) cells, probably as a result of the leakiness of the
doxycycline-regulated system.
REST-VP16 expression in myoblasts growing under
muscle differentiation conditions blocks muscle
differentiation and produces neuronal phenotype
To determine the effect of the expression of REST-VP16
in C2C12 cells grown under muscle-differentiation con-
ditions, we grew C2C12 and C2C12-RV cells with low
concentrations of growth factors C2C12(D) and C2C12-
RV(D) (+ and −Dox) for 6 d. A light-microscopic exami-
nation revealed that in the absence of REST-VP16 ex-
pression in C2C12(D) or C2C12-RV(D) (+Dox) cells, the
cells formed multinucleated muscle fibers (Fig. 3A), as
expected. In contrast, cells expressing REST-VP16
(C2C12-RV [−Dox] cells) did not form muscles. Instead,
they formed mononucleated cells, some of which had
long, neurite-like structures. To further characterize
these cells, we performed a Western blot analysis for
muscle and neuronal proteins. As shown in Figure 3B,
REST-VP16 was not detected in C2C12(D) cells and
C2C12-RV(D) (+Dox) cells, and the myosin heavy chain
(MHC) gene, a marker for differentiated muscles, was
detected. Expression of synapsin, a target of REST-VP16,
was not detected in C2C12(D) cells. A low level of syn-
apsin expression was detected in C2C12-RV(D) (+Dox)
cells, presumably because of the leakiness of the doxy-
cycline system, similar to that seen earlier (Fig. 2A). In
contrast, C2C12-RV(D) (−Dox) cells produced the REST-
VP16 protein and a high level of synapsin but did not
express MHC. Interestingly, C2C12-RV(D) (−Dox) cells
also produced MAP2, indicating that expression of
REST-regulated neuronal differentiation genes through
REST-VP16 also triggers the activation of other neuronal
differentiation genes that are not direct targets of REST/
NRSF. This correlation between REST-VP16 and MAP2
expressions was observed in almost all cells.
To confirm the inverse correlation between REST-
VP16 expression and MHC expression, C2C12(D),
C2C12-RV(D) (+Dox), and C2C12-RV(D) (−Dox) cells
were subjected to double immunofluorescence imaging
with anti-VP16 and anti-MHC antibodies. Expression of
MHC, but not REST-VP16, was observed in C2C12(D)
cells (Fig. 3C). In contrast, C2C12-RV(D) (−Dox) cells did
not express MHC but did express REST-VP16. The leaky
growth conditions allowed some C2C12-RV(D) (+Dox)
cells to express REST-VP16 and some to express MHC.
However, the cells that expressed REST-VP16 did not
express MHC, and the cells that expressed MHC did not
express REST-VP16. Thus, these experiments showed
that expression of REST-VP16 in C2C12 cells under
muscle differentiation conditions blocked muscle forma-
tion and MHC gene expression and caused the expres-
sion of neuronal terminal differentiation marker genes,
some of which are targets of REST/NRSF and others not.
The differentiation of C2C12 cells into muscle follows
a very well-defined pathway, expressing several muscle
differentiation factors in a sequential fashion (Walsh and
Perlman 1997; Odelberg et al. 2000; McGann et al. 2001;
Shen et al. 2003). Myogenin is one such factor that ap-
pears at the onset of muscle differentiation in C2C12
cells at ∼2 d in muscle differentiation medium (Shen et
al. 2003). To examine whether REST-VP16-mediated en-
try of C2C12-RV cells to the neuronal pathway occurred
before they entered the muscle differentiation pathway,
or whether C2C12-RV cells had to wait until they en-
tered the muscle differentiation pathway, we assayed the
Western blot in Figure 3D with an anti-myogenin anti-
body. The level of actin expression was used as an inter-
Figure 3. Stable expression of functional
REST-VP16 in myoblasts growing under
muscle differentiation conditions blocks entry
into the muscle differentiation pathway, subse-
quent muscle formation, and the MHC gene ex-
pression, and causes the expression of neuronal
differentiation genes and formation of neurite-
like structures, but does not cause expression
of glial differentiation genes. (A–C) C2C12,
C2C12-RV (+Dox), and C2C12-RV (−Dox) cells
were cultured in DMEM with 2% horse serum
for 6 d [C2C12(D), C2C12-RV(D) (+Dox), and
C2C12-RV(D) (−Dox), respectively] and exam-
ined by light microscopy (A), Western blot
analysis (B), and fluorescent microscopy (C).
Anti-MAP2, anti-myosin heavy chain, and
anti-synapsin antibodies were used. (D) Cell ex-
tracts prepared from C2C12 and C2C12-RV
(−Dox) cells at various days in differentiation
medium (day) were assayed by Western blotting
with anti-GFAP and anti-myogenin antibodies.
Anti-actin was used as an internal control.
Mouse brain extract was used as a positive con-
trol for GFAP expression.
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nal control, as before. As shown in Figure 3D, the onset
of myogenin expression appeared in C2C12 cells at ap-
proximately day 2 of muscle differentiation and then de-
creased with further differentiation, as expected (Shen et
al. 2003). In contrast, C2C12-RV cells did not show myo-
genin expression during any time of their differentiation,
indicating that REST-VP16 expression in C2C12-RV
cells growing under muscle differentiation conditions
immediately turned them towards the neuronal pathway
without entering the muscle differentiation pathway.
To confirm that C2C12-RV(D) cells did not express
glial markers, such as glial fibrillary acidic protein
(GFAP), cell extracts prepared from C2C12 and C2C12-
RV cells at various days in differentiation medium were
subjected to Western blotting analysis with anti-GFAP
antibody. Mouse brain extract was used as a positive
control for the expression of GFAP, and anti-actin anti-
body was used as an internal control. As shown in Figure
3D, GFAP was not expressed in any of these cells, indi-
cating that REST-VP16 expression in C2C12 cells con-
verted them only into neuronal phenotype.
Stable REST-VP16 expression in myoblasts enables
them to survive mitotic inhibitors and exhibit
neuronal phenotype
To examine whether C2C12-RV(D) (−Dox) cells that are
grown under muscle differentiation conditions can sur-
vive in the presence of mitotic inhibitors, a property of
nondividing neurons, C2C12-RV(D) (−Dox) cells were
further cultured for 14 d in the presence of mitotic in-
hibitors. The cells were then examined by light and im-
munofluorescence microscopy with anti-MAP2 and
anti-neurofilament antibodies. As shown in Figure 4A,
most of the C2C12-RV(D) (−Dox) cells, unlike the
C2C12 cells, survived the mitotic inhibitors, and ex-
pressed the MAP2 and neurofilament proteins.
To determine the changes in the global gene expres-
sion patterns of the various cell types, we performed
gene expression profiling of C2C12, C2C12(D), and
C2C12-RV(D) (−Dox) cells using Affymetrix mouse
chips. A large number of genes were differentially ex-
pressed among the three cell types. The genes most dif-
ferentially expressed in the C2C12-RV(D) (neuron) cells
compared with the C2C12(D) (muscle) cells are shown in
the Supplemental Material (Supplementary Table 1S).
Likewise, the genes most differentially expressed in
C2C12(D) cells in comparison to C2C12-RV(D) cells are
shown in Supplementary Table 2S. The C2C12(D) cells
expressed mostly muscle differentiation genes, as ex-
pected, and the C2C12-RV(D) cells expressed a large
number of neuronal differentiation genes (Schoenherr et
al. 1996; Lunyak et al. 2002). These genes included
widely used neuronal markers, such as MAP2 and neu-
ronal -tubulin, but also neuronal receptors such as gly-
cine receptor, glutamate receptor, adrenergic receptor,
cholinergic receptor, etc. They also included neuronal
channels, such as voltage-gated calcium channel, cal-
cium-activated chloride channel, voltage-gated potas-
sium channel, voltage-gated sodium channel, etc.
Among the topmost up-regulated genes in the C2C12-
RV(D) cells were the genes that code for components of
neuroendocrine secretory vesicles (Tooze et al. 2001),
such as secretogranin II, chromogranin A, and brain-spe-
cific Purkinje cell protein 4. We performed a Western
blot analysis with an anti-secretogranin II antibody that
confirmed that secretogranin II was expressed only in the
C2C12-RV(D) (−Dox) cells, not in the C2C12 (−Dox),
C2C12(D) (−Dox), or C2C12-RV(D) (+Dox) cells (Fig. 4B).
To further characterize the neuronal properties of
C2C12-RV(D) (−Dox) cells, we performed an RT–PCR
assay to determine the expression of several neuronal
genes in C2C12(D) and C2C12-RV(D) (−Dox) cells. As
shown in Figure 4C, several well characterized neuronal
REST-target genes such as neuronal -tubulin, SCG10,
Figure 4. Stable REST-VP16 expression
in myoblasts enables them to survive mi-
totic inhibitors and exhibit neuronal phe-
notype. (A) C2C12-RV cells were cultured
with and without Dox in differentiation
medium without mitotic inhibitors for 6 d
and then with mitotic inhibitors for an-
other 14 d. These cells were then exam-
ined by immunofluorescence imaging
with anti-MAP2 and anti-neurofilament
(NF) antibodies. (B) Expression of secreto-
granin II in C2C12-RV(D) (−Dox) cells.
Cell extracts from C2C12, C2C12(D),
C2C12-RV(D) (+Dox), and C2C12-RV(D)
(−Dox) cells were subjected to a Western
blot analysis with anti-secretogranin II an-
tibody. Anti-actin was used as an internal
control. (C) Expression of neuronal mark-
ers, such as neuronal -tubulin, SCG10, synapsin (syn), BDNF, and Lrrn1 in C2C12-RV(D) (−Dox) cells but not in C2C12(D) (−Dox)
cells as assayed by RT–PCR. Actin was used as an internal control. (D) Expression of synaptophysin and synaptotagmin in C2C12-
RV(D) (−Dox) cells. Immunofluorescence analysis was performed with C2C12(D) and C2C12-RV(D) (−Dox) cells using anti-synapto-
physin (Syp) and anti-synaptotagmin (Syt) antibodies. Cell nuclei were stained with DAPI.
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synapsin, and BDNF were up-regulated in C2C12-RV(D)
(−Dox) cells compared with C2C12(D) cells. Interest-
ingly, C2C12-RV(D) (−Dox) cells but not C2C12(D) cells
also expressed leucine-rich repeat protein 1, neuronal
(Lrrn 1), a neuronal gene that is not known to be a direct
target of REST/NRSF but was observed in the Affymetrix
microarray data.
To further characterize the neuronal properties of
C2C12-RV(D) (−Dox) cells by immunofluorescence as-
say, we stained C2C12(D) and C2C12-RV(D) (−Dox) cells
with anti-synaptophysin and anti-synaptotagmin anti-
bodies. Synaptophysin is a known target of REST/NRSF
(Schoenherr et al. 1996), and synaptotagmin was found to
be up-regulated in C2C12-RV(D) cells in the Affymetrix
microarray data (Supplementary Table 1S). As shown in
Figure 4D, C2C12-RV(D) but not C2C12(D) cells ex-
pressed these neuronal markers both in the cell body and
in neurites, as expected (Dandoy-Dron et al. 2003; Ogo-
shi and Weiss 2003). Thus, these experiments indicated
that there was a global change in the gene expression
profiles of these cell types and that REST-VP16-express-
ing myoblasts began expressing a large number of neu-
ronal genes upon differentiation.
REST-VP16 expression in myoblasts produces neurons
with physiological activities
Depolarization-dependent calcium influx is an intrinsic
property of synaptic vesicles, occurs in both mature and
developing neuronal processes, and is independent of the
presence of synaptic contacts (Bischofberger and Schild
1995; Matteoli et al. 1995; Pincus et al. 1998; Roy et al.
2000; Shen et al. 2003). This influx also occurs in func-
tional muscle fibers (Chawla et al. 2001). To determine
whether C2C12-RV(D) (−Dox) cells also undergo depo-
larization-dependent calcium influx, we measured intra-
cellular Ca++ levels by loading live C2C12, C2C12(D),
and C2C12-RV(D) cells with the fluorescent calcium in-
dicator Fluo-3 in the absence of Dox and examined them
with a confocal laser system. Fluo-3 is practically non-
fluorescent unless bound to Ca++. These cells were then
depolarized with high K+, and the fluorescence was mea-
sured every 0.25 sec for a total of 5 sec. As shown in
Figure 5, there was a rapid, reversible calcium influx in
response to K+ in C2C12(D) and C2C12-RV(D) cells but
not C2C12 cells. Thus, both C2C12(D) and C2C12-
RV(D) cells showed physiological activity, namely, de-
polarization-dependent calcium influx. C2C12(D) and
C2C12-RV(D) cells were cultured under similar condi-
tions, which suggests that the neuronal properties of
C2C12-RV(D) cells are not due to the differences in cul-
ture conditions but are inherent properties of these cells.
Because depolarization-dependent calcium influx is a
property of both neurons and muscles, we wanted to ex-
amine other physiological properties that are specific to
neurons. Synaptic vesicle recycling is a property of living
nerve terminals, and the fluorescent dye FM1-43 is fre-
quently used to label nerve terminals undergoing synap-
tic vesicle recycling (Betz and Bewick 1992). The dye,
which is fluorescent upon excitation at 470 nm, can be
internalized from the culture medium during synaptic
vesicle cycling with high K+. It does not transfer from
internalized vesicles to an endosome-like compartment
during the recycling process, and therefore it is possible
to measure fluorescence (Murthy and Stevens 1998). Fur-
thermore, each fluorescent spot is believed to be a clus-
ter of hundreds of synaptic vesicles (Betz and Bewick
1992). This is an inherent property of neurons and is not
observed in muscles. To determine whether C2C12(D)
and C2C12-RV(D) cells, both of which underwent depo-
larization-dependent calcium influx, also experienced
synaptic vesicle recycling, these cells were loaded with
FM1-43 in high-KCl buffer and then washed to remove
excess dye on the plasma membrane. The internalization
of FM1-43 was then detected by excitation at 470 nm,
and the fluorescent spots were examined by fluorescence
microscopy. Fluorescent spots were observed in the neu-
rites of C2C12 RV(D) cells but not in C2C12(D) cells or
C2C12 myoblasts (Fig. 6A), indicating that C2C12-
RV(D) cells have the properties of functional neuron-spe-
cific synapses.
Glutamate-induced calcium influx is another intrinsic
property of neurons. To determine whether C2C12-
RV(D) cells have this property, we measured the cells’
Figure 5. Stable expression of REST-
VP16 in myoblasts growing under
muscle differentiation conditions pro-
duced neurons with physiological prop-
erties. Differentiated C2C12 and C2C12-
RV cells show depolarization-dependent
calcium influx. C2C12, C2C12(D) or
C2C12-RV(D) (−Dox) cells were loaded
with 25 µM Fluo-3 AM for 60 min at
room temperature. Fluo-3 AM solution
was replaced with high-KCl Ringer solu-
tion, and an image was taken at every 0.25
sec for a total of 5 sec after depolarization.
The results of three independent experi-
ments with C2C12-RV(D) (−Dox) cells are
shown. Fluorescence intensity for experi-
ment is shown in the bottom panel.
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intracellular Ca++ levels with and without glutamate,
using the fluorescent calcium indicator Fluo-3 as de-
scribed above. As shown in Figure 6B, C2C12-RV(D)
cells but not C2C12 cells underwent a rapid increase in
intracellular Ca++ in the presence of glutamate as evi-
denced by the fluorescent signal, which returned to base-
line upon wash. Thus, taken together, the above experi-
ments showed that C2C12-RV(D) cells exhibit physi-
ological properties of neurons.
In vitro differentiated neurons produced
by REST-VP16-expressing myoblasts incorporate
into adult brain without forming tumors
Next, we wanted to examine whether in vitro differen-
tiated neurons produced by REST-VP16-expressing myo-
blasts could survive in the brain and whether they
formed tumors. We injected C2C12 and in vitro differ-
entiated C2C12-RV(D) cells into the cerebella of mice.
We performed these experiments with already differen-
tiated neurons to exclude the possibility of cell fusion in
the brain as a mechanism of neuron formation. We sac-
rificed the mice 8 wk later, and examined the status of
the injected cells in paraffin sections of the brains by
hematoxylin-eosin and immunohistochemical staining
with anti-VP16 antibodies. As a control, we also used a
neuronal tumor (meduloblastoma) cell line. However,
the latter sets of mice were sacrificed after 4 wk, as they
showed signs of morbidity by that time. Whereas the
medulloblastoma tumor cell line formed a large tumor
within 4 wk, neither C2C12 nor C2C12-RV(D) cells
formed tumors after 8 wk (Supplementary Fig. 1S). As
shown in Figure 7, C2C12-RV(D) cells, which are tagged
with VP16 protein, survived in the brain as detected by
the presence of signal with anti-VP16 immunohisto-
chemistry, and appeared to be distributed in the brain
structures [the magnified view of C2C12-RV(D) cells
shows nuclear localization of VP16 signal]. To determine
whether the VP16-positive C2C12-RV(D) cells still ex-
pressed neuronal differentiation markers, we subjected
them to a double-immunostaining assay with the anti-
neuronal -tubulin antibody (Tuj1). As shown in Figure
7, whereas the endogenous neuronal cells expressed only
neuronal -tubulin and not VP16, as expected, C2C12-
RV(D) cells expressed both VP16 (nuclear) and neuronal
-tubulin (cytoplasmic), indicating that the neuronal
cells can survive in the brain and continue to express
neuronal markers.
Discussion
As described above, C2C12 myoblasts have been con-
verted into various cell types, and C2C12 myotubes have
been induced to dedifferentiate and redifferentiate into
various cell types, but not neurons. Here, we found that
direct activation of terminal neuronal differentiation
Figure 6. Stable expression of REST-VP16 in myoblasts grow-
ing under muscle differentiation conditions produced neurons
with physiological properties. (A) Uptake of FM1-43 by C2C12-
RV(D) (−Dox) shows synaptic vesicle cycling with KCl depolar-
ization. C2C12, C2C12(D) or C2C12-RV(D) (−Dox) cells were
loaded with 15 µM FM1-43 with high-KCl Ringer solution for 5
min at room temperature. Cells were washed with Ringer so-
lution without a dye for 15 min to remove superficial FM1-43
on plasma membrane. The results of two independent experi-
ments are shown. (B) Differentiated C2C12-RV cells show glu-
tamate-induced calcium influx. C2C12 or C2C12-RV(D) (−Dox)
cells were loaded with 25 µM Fluo-3 AM for 60 min at room
temperature, and the cells were treated as described in Figure 5,
except that 10 µM glutamate was added instead of KCl. The
fluorescent signal returned to baseline upon wash.
Figure 7. In vitro differentiated neurons pro-
duced by REST-VP16-expressing myoblasts
incorporate into adult brain without forming
tumors. C2C12 and C2C12-RV(D) cells were
inoculated into the cerebellum of adult nude
mice. The mice were sacrificed after 8 wk and
their brain tissues were formalin-fixed, em-
bedded in paraffin, and used for light micro-
scopic evaluation after staining with H&E or
by immunohistochemical analysis with anti-
VP16 antibody followed by anti-neuronal -tubulin (Tuj1) antibody. The magnified view of C2C12-RV(D) cells shows nuclear local-
ization of VP16 signal and cytoplasmic localization of Tuj1 signal. Endogenous neuronal cells show cytoplasmic localization of Tuj1
signal alone.
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genes that are targets of REST/NRSF (mostly structural
genes) triggered the activation of other terminal neuro-
nal differentiation genes that are not direct targets of
REST/NRSF and produced neurons from C2C12 myo-
blasts. These findings suggest that such experimental
manipulations might be useful in converting other types
of progenitor cells to neurons and that the manipulations
may circumvent inhibitory regulation in progenitor cells
traversing either the nonneuronal differentiation path-
ways or early stages of neuronal differentiation path-
ways.
Although REST-VP16 converted myoblasts into neu-
rons, expression of REST-VP16 in fully differentiated
muscle fibers failed to convert their fate (data not
shown), suggesting that REST-VP16-mediated produc-
tion of neuronal phenotype is less effective in fully dif-
ferentiated cell types. Further studies should be per-
formed to determine whether REST-VP16-mediated ma-
nipulation of C2C12 myoblasts, which produced a rapid
fate change, also involves a global chromatin modifica-
tion, as was recently shown to occur during normal NSC
development (Xinyu Zhao 2003). REST/NRSF does in-
duce long-term chromatin repression by interacting with
the cellular cofactors (Jepsen et al. 2000; Lunyak et al.
2002). Because REST-VP16 binds to the same DNA-bind-
ing site as does REST/NRSF but functions as an activator
instead of a repressor (Immaneni et al. 2000; Lawinger et
al. 2000), we believe that REST-VP16 will block REST/
NRSF-mediated chromatin modification. We are cur-
rently examining the chromatin modification induced
by REST/NRSF and REST-VP16 in our mammalian chro-
matin reconstitution system (Rastelli et al. 2001). In ad-
dition, myogenic progenitors with enhanced regenera-
tion capabilities were recently isolated (Jankowski et al.
2002), and it will be interesting to determine the role of
REST-VP16 expression in those cells. Finally, neurons
dying from ischemic insult have been shown to re-ex-
press REST/NRSF (Calderone et al. 2003), so experi-
ments should be performed to determine whether ex-
pression of REST-VP16 can reverse such neuronal death.
The wild-type huntingtin protein was recently found to
bind to REST/NRSF and thereby sequester REST/NRSF
in the cytoplasm (Zuccato et al. 2003). It was postulated
that in the pathology of Huntington disease, the REST/
NRSF-huntingtin protein interaction is lost, causing
REST/NRSF to enter the nucleus and repress its target
genes. It will be exciting to examine whether REST-




The NheI/XhoI fragment of pcDNA3.1-REST-VP16 (Immaneni
et al. 2000) was subcloned into the NheI/XhoI-digested plasmid
pBig2r (Strathdee et al. 1999). The clone obtained was confirmed
by sequencing the junction region. Construction of pNaCh,
pNaChRE1, pTLuc, pRE.Tluc, pREST/NRSF, pGal4-VP16, and
pREST-VP16 has been described elsewhere (Immaneni et al.
2000; Lawinger et al. 2000). The pCMV-GAL was purchased
from Stratagene.
Cell culture
The mouse myoblast C2C12 cells were purchased from Ameri-
can Type Culture Collection. C2C12 cells were maintained in
Minimal Essential Medium (Invitrogen) containing 10% fetal
calf serum (FCS) at 37°C in a humidified atmosphere of 5% CO2
in air. The cells were never grown to confluence. To induce
muscle differentiation, the cells were grown to subconfluence
in 10% fetal calf serum–Dulbecco’s Modified Eagle’s Medium
(DMEM), and then the medium was changed to DMEM con-
taining 2% horse serum (Invitrogen). The medium was changed
at least every 2 d. Culture vessels coated with poly-l-lysine (fi-
nal 20 µg/mL in distilled water; Sigma) were used in the assays.
For both calcium imaging and FM1-43 staining, cells were dif-
ferentiated for 10 d on glass cover slips coated with 0.005%
poly-L-lysine and 20µg/mL laminin.
Stable transfection
C2C12 cells were plated into 60-mm plates at a density of
5 × 105 per dish the day before the transfection. Two milligrams
of pBig2r-REST-VP16 was transfected with 6 µL of Fugene 6
(Roche Diagnostics) according to the manufacturer’s instruc-
tions. Doxycycline (2 µg/mL; Sigma) was added to the culture
and refreshed every 2 d. After 10 d of hygromycin B (750 µg/mL;
Roche) selection, colonies were picked and expanded. Doxycy-
cline-inducible clones were selected by induction of REST-VP16
2 d after the removal of doxycycline and identified by Western
blot analysis. Two clones (clones 2 and 7) expressed high levels
of REST-VP16. After selection, clones were maintained in me-
dium containing 500 µg/mL hygromycin B. During the assays,
the concentration of hygromycin B was reduced to 250 µg/mL to
avoid removal of the transgene.
SDS-PAGE and Western blotting
Cells were treated as indicated in the figures, rinsed, and lysed
directly in Laemmli sample buffer (Bio-Rad). The lysates were
mixed vigorously in a vortex mixer, boiled for 5 min, and sub-
jected to SDS-PAGE. Western blotting was performed as de-
scribed (Immaneni et al. 2000) using Hybond-P PVDF mem-
branes (Amersham Biosciences) and ECL-plus reagent (Amer-
sham).
Antibodies
The antibodies used were anti-VP16 (1:1000; Clontech), anti-
synapsin I (1:1000; MAB355; Chemicon), anti-actin (1:2000,
I-19, Santa Cruz Biotech), anti-MAP2 (1:10000 for IF, 1:1000 for
Western; HM-2; Sigma), anti-unique -tubulin (III; 1:1000;
Tuj1; Covance Research Products), anti--tubulin (1:10000; B-5-
1-2; Sigma), anti-myosin heavy chain (1:10; MF20; Developmen-
tal Studies Hybridoma Bank), anti-secretogranin II antibody (1:
100; QED Bioscience; Roche), anti-synaptophysin I (1:200;
Chemicon, catalog no. mab368), anti-synaptotagmin (1:200;
Chemicon, catalog no. AB5600), horseradish peroxidase-conju-
gated anti-mouse, anti-rabbit IgG (H+L; 1:20000; Amersham),
HRP-conjugated anti-goat IgG (1:20000; Santa Cruz), fluores-
cein anti-rabbit IgG (1:250; Vector Lab), and Cy2-labeled anti-
mouse IgG (H+L; 1:1000; Amersham). For Western blotting,
anti-neurofilament-160/200kD (1:50; RMdO-20; Zymed), anti-
GFAP (1:500; DAKO), and anti-myogenin (1:200; Santa Cruz)
antibodies were used.
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Reporter gene assays
C2C12 cells and C2C12-RV clone cells were plated into poly-l-
lysine-coated 24-well plates at a density of 8 × 104 cells per well
and 1 × 105 cells per well, respectively, the day before transfec-
tion. A combination of 100 ng of pTLuc, pRE.Tluc, or
pcDNA3.1 and 10 ng of pCMV-GAL was transfected with Li-
pofectamine 2000 reagent (Invitrogen) according to the manu-
facturer’s instructions. During the transfection, doxycycline
was removed from the culture. Six hours after the transfection,
the cells were trypsinized, divided into two wells of a six-well
plate with or without doxycycline, and cultured for 42 h. The
harvested cells were assayed for luciferase and -galactosidase
as described (Immaneni et al. 2000; Lawinger et al. 2000).
Immunofluorescence analysis of cells
Cells were fixed for 20–30 min at room temperature with either
4% paraformaldehyde in phosphate-buffered saline (PBS) or
10% buffered formalin, rinsed in PBS, permeabilized, and
blocked in blocking buffer (5% nonfat dry milk [Nestle], 0.3%
Triton X-100 [Sigma], and PBS) for 30 min at room temperature.
Primary antibodies were diluted in the blocking buffer and in-
cubated overnight at 4°C in humidified conditions. Secondary
antibodies were diluted in PBS and incubated for 1 h at room
temperature. For nuclear staining, Hoechst 33328 (Molecular
Probes) was used at 0.1 µg/mL in water. Photographs were taken
with a Hamamatsu 5880 color CCD camera with a Leica DMR
microscope. Double-label images were assembled in Adobe Pho-
toshop. Alternatively, stained cells were covered with slow-fade
antifade containing 1µg/mL DAPI (Molecular Probes) and cov-
ered with a coverslip. Staining of cells was observed using a
Leica Epifluorescence microscope.
Gene profiling assay
Total RNA was extracted from C2C12 myoblast cells,
C2C12(D) muscle cells, and C2C12-RV(D) neuronal cells using
a QIAGEN RNA extraction kit and was subjected to Affymetrix
U74Av2 mouse chips. The data were quantified using Af-
fymetrix Microarray Analysis Suite (MAS) 5.0. Estimates of sig-
nal intensity and detection p-values were loaded into S-Plus for
further analysis. We applied a detection filter to determine
which genes should be retained for further analysis; we retained
genes that had a detection p-value less than 0.05 on at least one
array. Of the 12,488 probe sets on the array, 7496 passed this
filter. The remaining 4992 probe sets were dropped. We log-
transformed the data and performed a hierarchical cluster analy-
sis to determine which pair of samples was most similar. We
used average linkage and a similarity measure based on the
Pearson correlation coefficient. By relying on the values from
individual probe pairs, we used MAS 5.0 to perform a Wilcoxon
signed rank test to compare genes from two chips. Pairwise
comparisons were carried out in this manner for each of the
three desired comparisons. A summary of the top up-regulated
genes in C2C12-RV(D) cells compared to C2C12(D) cells and
the top up-regulated genes in C2C12(D) cells compared with
C2C12-RV(D) cells are shown in Supplementary Tables 1S and
2S, respectively.
RT–PCR assay
C2C12, or C2C12RV cells were seeded at a density of 5 × 105
cells per 10-cm Petri dish coated with 0.1 mg/mL polylysine and
0.1µg/mL of laminin. The cells were grown in DMEM contain-
ing 2% horse serum at 37°C and 5% CO2 tension. At the end of
10 d, cells were harvested using a cell scraper and washed with
1× PBS. Total RNA was prepared from these cells using the
RNeasy Kit from QIAGEN. RNAs were quantitated spectropho-
tometrically, and 100 ng of total RNA per sample was used for
RT–PCR. Primers used in these reactions had the following se-
quence: mouse Lrrn1-S585-604, 5-CCGGAATTCTTTTC
CAGTGA-3; mouse Lrrn1-AS815-796, 5-AAACACAAAGC
TGGGGACAC-3; mouse SCG10-S1009-1029, 5-TCCAACC
GAAAAATGAGGTC-3; mouse SCG10-AS1177-1158, 5-GGC
AGGAAGCAGATTACGAG-3; mouse BDNF-S3612-3631, 5-
TTGTTTTGTGCCGTTTACCA-3; mouse BDNF-AS3842-
3722, 5-GGTAAGAGAGCCAGCCACTG-3; mouse SYN1-
S1127-1146, 5-TGTCGGGTAACTGGAAGACC-3; mouse
SYN1-AS1360-1341, 5-AGTTCCACGATGAGCTGCTT-3;
mouse -Actin AS-841, 5-CGCTCGTTGCCAATAGTGATGA
CCTG-3; and mouse -actin S-57, 5-GTCCACACCCG
CCACCAGTT-3. The initial reverse transcription reaction
was carried out using the RT–PCR kit as per manufacturer’s
instructions (QIAGEN). Thereafter, the cDNA was amplified
for 25 cycles under the following conditions: Melting at 94°C
for 1 min, annealing at 55°C for 1 min, and extension at 72°C for
1 min. The reaction products were analyzed with 2% agarose gel
electrophoresis.
Mitotic inhibition studies
Cells were cultured for 6 d in 2% horse serum-DMEM and then
for 14 d in inhibitor medium (2% horse serum–DMEM and mi-
totic inhibitors). The final concentrations of inhibitors were 10
µM 5-fluoro-2-deoxyuridine, 10 µM uridine, and 1 µM cytosine
-d-arabinofuranoside (Sigma).
Calcium imaging
Living-cell microscopy to detect depolarization-dependent cal-
cium influx was carried out as described (Bischofberger and
Schild 1995). A confocal laser system (Olympus Fluoview
FV500) and the fluorescent calcium indicator Fluo-3 (Molecular
Probe) were used to measure the intracellular free calcium con-
centration. Each cell was loaded with Fluo-3 and depolarized
with High KCl (100 mM) Ringer solution as described (Bischof-
berger and Schild 1995). Fluorescence was measured every 0.25
sec for a total of 5 sec. For the glutamate experiment, 10µM
glutamate was included in the Ringer solution.
FM1-43 staining
Cells were loaded with 15µM FM1-43 (Molecular Probes) dis-
solved in high-KCl (100 mM) Ringer (external [Na+] was reduced
by an equivalent amount) for 5 min at room temperature, and
washed in Ringer solution without a dye for 15 min to remove
superficial FM1-43. A dye was excited at 470 nm, and the emit-
ted fluorescence was collected at 540 nm.
Cerebellar inoculation of cells into mice
These experiments were performed following M.D. Anderson
Institutional Animal Care and Use guidelines. C2C12 and
C2C12-RV(D) (−Dox) cells were centrifuged, and 2 × 105 cells
present in 5 µL cell growth medium were inoculated in a group
of six mice for each experimental condition using an implant-
able guide-screw system we described elsewhere (Lal et al.
2000). This method, which uses a guide screw, a stylet, a modi-
fied Hamilton syringe with a 26-gauge needle, and an infusion
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pump, allows delivery of cells to a very specific location in the
brain. Several days before the inoculation, the guide screws
were placed in the dorsal cranium of mice. The animals were
anesthetized by intraperitoneal injection of 1.2% avertin solu-
tion made in sterile PBS per gram of body weight (100% avertin
solution: 10 g tribromoethylalcohol + 10 mL tertiary amyl alco-
hol) at a dosage of 15–17 µL per gram of body weight. The guide
screw entry site was marked at a point 2.5 mm lateral and 1 mm
anterior to the bregma, which is located directly above the cau-
date nucleus. A small, hand-controlled twist drill was used to
make the hole, and a specially devised screwdriver was used to
thread the screw into the hole and secure it. After a recovery
period of 7–10 d after the guide screws were placed, the cells
were inoculated. On the day of implantation, the cells were
harvested and resuspended in Ca++- and Mg++-free PBS. The cells
were kept on ice until implantation. Mice with the guide screws
in place were reanesthetized as described above. The cell sus-
pension was drawn into a Hamilton syringe, which was fitted
with a cuff to control the depth of injection. The needle of the
Hamilton syringe was slowly lowered into the center of the
guide screw until the cuff rested on the screw surface. Up to 10
mice attached to 10 syringes were positioned in a row in a
Harvard Apparatus infusion pump that provided continuously
controlled slow injection of the cells at a rate of 1 µL/min. After
the entire volume of the cell suspension was injected, the
needles were manually removed, and with a fine forceps, the
stylets were positioned in the screw holes to close the system
and prevent the injected cells from leaking after inoculation.
Immunhistochemical double-staining of mouse brain
paraffin sections
The mice were sacrificed by CO2 inhalation, and further proce-
dures were performed as described (Lawinger et al. 2000; Sim-
mons et al. 2001). Briefly, mouse brains were fixed in neutral
buffered formalin, dehydrated, and embedded in paraffin. Five-
micron sections were cut onto charged glass slides and used for
light microscopic evaluation after staining by hematoxylin-eo-
sin (H&E). For immunostaining, sections were deparaffinized
and rehydrated in graded ethanols to PBS. Endogenous peroxi-
dase activity was blocked using 3% hydrogen peroxide for 30
min at room temperature. Blocking buffer (10% bovine serum in
PBS) was applied for 30 min at room temperature in a humidi-
fied chamber. Anti-VP-16 antibody (Clontech) was used as a
1:50 dilution in blocking buffer overnight at 4°C. Sections were
washed three times in PBS the following day. Conjugated anti-
rabbit antibody (Envision kit, Dako) was applied for 30 min at
room temperature. After washing, the staining was visualized
using DAB as a chromogenic substrate (Dako) according to the
manufacturer’s instructions. The sections were mounted for vi-
sualization of staining. The cover slip was them removed and
the sections rehydrated. Antigen retrieval was performed in 10
mM sodium citrate at pH 6.0, using a microwave-pressure
cooker (Kmart) for 10 min at high power, followed by 12 min at
20% power. The slides were cooled for 30 min, washed in PBS,
and incubated in blocking buffer for 30 min at room tempera-
ture. An antibody to neuronal class III -tubulin (TuJ1, Co-
vance) was diluted 1:10 in blocking buffer and added to the
slides. Following an overnight incubation at 4°C in a humidified
chamber, the slides were washed in PBS. Biotinylated anti-
mouse antibody (Vector Labs) was added for 30 min at room
temperature. The “ABC” reagent was then added and the sub-
strate was developed using a blue chromogen (Vector VIP kit)
according to the manufacturer’s instructions. Following dehy-
dration in graded ethanols, the slides were mounted and photo-
graphed. Specimens were then examined under light micro-
scope and photographed.
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